<DOC>
	<DOC>NCT02826382</DOC>
	<brief_summary>A phase 0 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.</brief_summary>
	<brief_title>Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>histologically confirmed prostate cancer. known or suspected bone metastases referred for a clinical [99mTc]MDP scan Estimated creatinine clearance (GFR) &lt; 30 mL/min (calculated), history of hyperparathyroidism, • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician, • Any current medical condition, illness, or disorder as assessed by medical record review and/or selfreported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>